Short Interest in Tema Heart & Health ETF (NASDAQ:HRTS) Decreases By 40.1%

Tema Heart & Health ETF (NASDAQ:HRTS) was the recipient of a significant drop in short interest in the month of June. As of June 30th, there was short interest totaling 583 shares, a drop of 40.1% from the June 15th total of 974 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average daily volume of 8,175 shares, the short-interest ratio is presently 0.1 days.

Hedge Funds Weigh In On Tema Heart & Health ETF

A number of institutional investors have recently made changes to their positions in HRTS. Kestra Advisory Services LLC purchased a new position in shares of Tema Heart & Health ETF during the fourth quarter valued at approximately $27,000. JPMorgan Chase & Co. acquired a new position in Tema Heart & Health ETF in the 2nd quarter valued at $63,000. Citadel Advisors LLC acquired a new position in Tema Heart & Health ETF in the 3rd quarter valued at $243,000. Brookstone Capital Management purchased a new position in shares of Tema Heart & Health ETF during the 4th quarter worth $364,000. Finally, Royal Bank of Canada boosted its holdings in shares of Tema Heart & Health ETF by 8.8% during the first quarter. Royal Bank of Canada now owns 21,083 shares of the company’s stock worth $710,000 after purchasing an additional 1,703 shares during the last quarter.

Tema Heart & Health ETF Stock Performance

HRTS stock traded down $0.08 during trading on Friday, reaching $36.44. 1,056 shares of the company were exchanged, compared to its average volume of 6,026. The stock’s 50 day moving average price is $34.84 and its 200 day moving average price is $34.82. Tema Heart & Health ETF has a 52-week low of $27.24 and a 52-week high of $37.57. The company has a market cap of $54.30 million, a P/E ratio of 22.06 and a beta of 0.63.

About Tema Heart & Health ETF

The Tema Obesity & Cardiometabolic ETF (HRTS) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that concentrates on companies focused on the treatment of cardiovascular diseases and/or metabolic diseases from companies all around the world. Using both top-down and bottom-up stock selection, the fund identifies innovative companies deemed attractive. HRTS was launched on Nov 20, 2023 and is issued by Tema.